Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 12, 2024 | Sciensus partners with Sentynl Therapeutics to become the exclusive distribution partner of NULIBRY® in Europe | Sciensus, a life sciences business, to become the exclusive distribution partner for Sentynl’s drug NULIBRY in Europe. We are pleased to be partnering with Sentynl to provide programmes which will offer patients in Europe access to potentia... |
| Oct 13, 2021 | Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition | NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licensing partner Senty... |
Reviews 0
FAQ about Sentynl Therapeutics
What has the press written about Sentynl Therapeutics?
Parsers VC has collected 3 articles mentioning Sentynl Therapeutics, among them “Sciensus partners with Sentynl Therapeutics to become the exclusive distribution partner of NULIBRY® in Europe” (Jul 12, 2024) and “Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics ...” (Oct 13, 2021).
Is Sentynl Therapeutics still active?
Yes, Sentynl Therapeutics is active; its latest activity on Parsers VC dates from Aug 12, 2026.